Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.42 |
| ▸ | HPGDS | O60760 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | WDR5 | P61964 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16561340 | 0.80 | PDE10A (0.54) | PDE10A | |
| SCHEMBL20842474 | 0.74 | WDR5 (0.52) | PDE10AHPGDSALDH1A1WDR5NPC1 | |
| SCHEMBL16003544 | 0.72 | PDE10A (1.00) | PDE10A | |
| SCHEMBL16003531 | 0.72 | PDE10A (1.00) | PDE10A | |
| SCHEMBL16003542 | 0.72 | PDE10A (0.80) | PDE10A | |
| SCHEMBL16320654 | 0.72 | PDE10A (0.63) | PDE10AHPGDSWDR5 | |
| SCHEMBL408909 | 0.71 | WDR5 (0.52) | PDE10AALDH1A1WDR5NPC1RAB9A | |
| SCHEMBL16003541 | 0.71 | PDE10A (1.00) | PDE10A | |
| SCHEMBL16003699 | 0.71 | PDE10A (0.78) | PDE10A | |
| SCHEMBL16003574 | 0.71 | PDE10A (1.00) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440970-B2 | Pyrazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150133448-A1 | NOVEL PYRAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-14 | — | — | US | disclosed |
| US-20140378448-A1 | NOVEL PYRAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378448-A1 | NOVEL PYRAZOLE DERIVATIVE | PDE10A, PDE3A, PDE5A | PDE10A 1/4885MAPK8 1764/4885USP30 513/4885 |
| US-20150133448-A1 | NOVEL PYRAZOLE DERIVATIVE | PDE10A, PDE3A, PDE5A | PDE10A 1/4885MAPK8 1764/4885USP30 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.